Skip to search formSkip to main contentSkip to account menu

cixutumumab

Known as: Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
Antibody-Dependent Cellular CytotoxicityNCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2…
SummaryBackground: Type 1 insulin-like growth factor receptor (IGF-IR) signaling is often dysregulated in cancer. Cixutumumab, a… 
Highly Cited
2014
Highly Cited
2014
Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Purpose: To investigate the autocrine/endocrine role of Id1-induced insulin-like growth factor-II (IGF-II) in esophageal cancer… 
2014
2014
E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer.
4020 Background: Paclitaxel has activity in previously treated metastatic esophagus/GE junction cancer. Given activation of IGFR… 
2013
2013
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
6030 Background: Preclinical evidence supports clinical investigation of IGF-1R inhibitors alone, or combined with EGFR… 
2012
2012
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer…
97 Background: Vascular endothelial growth factor (VEGF)-mediated angiogenesis and insulin-like growth factor (IGF-IR)-mediated… 
2012
2012
Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
198 Background: Targeting a single pathway in pancreatic adenocarcinoma (PAC) did not impact the natural history of this… 
2012
2012
Phase II study of cixutumumab (IMC-A12) in thymic malignancies.
7033 Background: The IGF-1 receptor (IGF-IR) is expressed in thymoma (T) and thymic carcinoma (TC). Prolonged SD has been seen… 
2011
2011
Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors.
10004 Background: Preclinical and clinical data suggest that cixutumumab (IMC-A12), a fully human IgG1 monoclonal antibody… 
2010
2010
N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer.
TPS129 Background: Insulin-like growth factor (IGF) signaling has been implicated as a mechanism of resistance to therapies… 
2010
2010
Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma.
TPS220 Background: The somatostatin analogue octreotide is an established therapy offering symptom relief in patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)